PFE / Pfizer slashes outlook: Projects weak demand for Covid-19 vaccine and Paxlovid

High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or u more_horizontal

Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE more_horizontal

Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The comp more_horizontal

In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has be more_horizontal

Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. more_horizontal

Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in t more_horizontal

Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reporte more_horizontal

Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Trav more_horizontal